Announced
Completed
Synopsis
SK Group completed the acquisition of YpoKesi, a producer of gene and cell therapy products. Financial terms were not disclosed. "We are glad to advance into the gene therapy CMO business by investing in Yposkesi which has great capability and potential. We will spare no efforts to help Yposkesi grow fast in the global market," Jang Dong-Hyun, SK Group CEO.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.